NCT06504186View on ClinicalTrials.gov

The Use of Blinatumomab in Patients With NGS-MRD Relapsed B-ALL After Autologous/Allogeneic Transplantation

NANot yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

October 31, 2026

Conditions

B-ALL

Interventions

DRUG

Blinatumomab

"* Ph-negative B-ALL: bephedolumab (≥ 45 kg: 9 mcg/d D1-2, 28 mcg/d D3-14 or 28 mcg/d D1-14; \< 45 kg: 5 mg/m2/d D1-2, 15 mg/m2/d D3-14) in 28-day cycles for 3 cycles.~* Ph-positive B-ALL: treatment with bephytoin + TKIs, bephytoin (≥ 45 kg: 9 mcg/d D1-2, 28 mcg/d D3-14 or 28 mcg/d D1-14; \< 45 kg: 5 mg/m2/d D1-2, 15 mg/m2/d D3-14) in 28-day cycles for 3 cycles."

All Listed Sponsors

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER

NCT06504186 - The Use of Blinatumomab in Patients With NGS-MRD Relapsed B-ALL After Autologous/Allogeneic Transplantation | Biotech Hunter | Biotech Hunter